感染症関連の事業協力・ライセンス取引 (2019～2024年)

当レポートでは、感染症の治療薬開発に関する昨今 (2019～2024年) の事業協力・ライセンス取引の取引動向について分析し、全体的な取引形成件数の推移や、財務面 (支払条件) での傾向、主要企業による取引形成の動き、契約条件の傾向、適応症別 (治療標的別) の傾向などを調査すると共に、近年の主要な提携取引の詳細情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 感染症関連の取引形成の傾向

• イントロダクション
• 感染症関連の取引形成：長期的動向
• 感染症関連の取引形成：取引の種類別
• 感染症関連の取引形成：業界別
• 感染症関連の取引形成：開発段階別
• 感染症関連の取引形成：技術の種類別
• 感染症関連の取引形成：治療対象の適応症別

第3章 感染症関連の事業提携：財務面での条件

• イントロダクション
• 感染症関連の事業提携の開示されている財政的条件
• 感染症関連の事業提携：取引総額
• 感染症関連の事業提携：前払い金
• 感染症関連の事業提携：マイルストーン払い
• 感染症関連の事業提携：ロイヤルティ率

第4章 感染症関連の主な取引先と取引

• イントロダクション
• 感染症関連の提携で最も活動的な企業
• 感染症関連で最も活動的な企業の一覧
• 感染症関連の主要な取引：契約金額別

第5章 感染症の契約文書ディレクトリ

• イントロダクション
• 感染症関連の資本取引の動向：契約文章が閲覧可能な取引の場合

第6章 感染症関連の取引形成：治療標的別

• イントロダクション
• 感染症関連の取引形成：治療標的別
• 取引一覧
• 感染症関連の取引一覧、企業名別 (ABC順、2019～2024年)
• 感染症関連の取引一覧、技術の種類別 (2019～2024年)
• 取引の種類の定義
• Biopharma Research Ltd. について
• 現在の提携
• 現在の契約
• Current Partnering刊行の最近の分析題名

Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 1726 infectious disease deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of infectious diseases dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in infectious diseases dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the infectious diseases field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in infectious diseases dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of infectious diseases deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of infectious diseases deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in infectious diseases deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse infectious diseases collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Infectious Diseases Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of infectious diseases trends and structure of deals entered into by leading biopharma companies worldwide.

Infectious Diseases Collaboration and Licensing Deals includes:

• Trends in infectious diseases dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of infectious diseases deal records covering pharmaceutical and biotechnology
• The leading infectious diseases deals by value
• Most active infectious diseases licensing dealmakers

In Infectious Diseases Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Infectious Diseases Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious diseases dealmaking

• 2.1. Introduction
• 2.2. Infectious diseases partnering over the years
• 2.3. Infectious diseases partnering by deal type
• 2.4. Infectious diseases partnering by industry sector
• 2.5. Infectious diseases partnering by stage of development
• 2.6. Infectious diseases partnering by technology type
• 2.7. Infectious diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for infectious diseases partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for infectious diseases partnering
• 3.3. Infectious diseases partnering headline values
• 3.4. Infectious diseases deal upfront payments
• 3.5. Infectious diseases deal milestone payments
• 3.6. Infectious diseases royalty rates

Chapter 4 - Leading infectious diseases deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in infectious diseases partnering
• 4.3. List of most active dealmakers in infectious diseases
• 4.4. Top infectious diseases deals by value

Chapter 5 - Infectious diseases contract document directory

• 5.1. Introduction
• 5.2. Infectious diseases partnering deals where contract document available

Chapter 6 - Infectious diseases dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by infectious diseases therapeutic target
• Deal directory
• Deal directory - Infectious diseases deals by company A-Z 2019 to 2024
• Deal directory - Infectious diseases deals by technology type 2019 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Infectious diseases partnering since 2019
• Figure 2: Infectious diseases partnering by deal type since 2019
• Figure 3: Infectious diseases partnering by industry sector since 2019
• Figure 4: Infectious diseases partnering by stage of development since 2019
• Figure 5: Infectious diseases partnering by technology type since 2019
• Figure 6: Infectious diseases partnering by indication since 2019
• Figure 7: Infectious diseases deals with a headline value
• Figure 8: Infectious diseases deals with upfront payment values
• Figure 9: Infectious diseases deals with milestone payment
• Figure 10: Infectious diseases deals with royalty rates
• Figure 11: Active infectious diseases dealmaking activity since 2019
• Figure 12: Top infectious diseases deals by value since 2019